BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
CAMBRIDGE, Mass. and EXTON, Pa., Nov. 10, 2016 -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Idera’s Chief Executive Officer, Vincent Milano will provide a corporate overview the Stifel 2016 Healthcare Conference on Wednesday November 16, 2016 at 3:00 p.m. Eastern Time at the Lotte New York Palace Hotel.
Live audio webcast of Idera’s presentations will be accessible in the Investors and Media section of Idera’s website at http://www.iderapharma.com. Archived versions will also be available on the Company’s website after the event for 90 days.
About Idera Pharmaceuticals
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases. Idera’s proprietary technology involves designing synthetic oligonucleotide-based drug candidates to modulate the activity of specific TLRs. In addition to its TLR programs, Idera has used its proprietary knowledge to create a third generation antisense technology platform which inhibits the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit www.iderapharma.com.
Investor and Media Contact Robert Doody VP, IR & Corporate Communications 617-679-5515 (office) 484‐639‐7235 (mobile) [email protected]
